Rifaximin in Patients With Monoclonal Gammopathy

Clinical trial NCT03820817 · COMPLETED

Trial details

NCT number: NCT03820817
Sponsor: Emory University
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

IgA Monoclonal Gammopathy IgG Monoclonal Gammopathy IgM Monoclonal Gammopathy Light Chain Deposition Disease Monoclonal Gammopathy Smoldering Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia Gammopathy, Monoclonal Gammopathy Igg

Start date: 2019-05-15
Primary completion: 2025-11-30
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.